William Gradishar, MD, FASCO, FACP from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University speaks about Updates to…
Browsing: Breast
Breast Cancer
Erica L. Mayer, MD, MPH of the Dana-Farber Cancer Institute discusses Palbociclib with adjuvant endocrine therapy in early breast cancer…
Joanne Mortimer, MD from the City of Hope speaks about Breast Cancer: Her Experience, Research, And The Current Treatment LandscapeLink…
Vered Stearns, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins discusses Taking an individualized approach to preventing…
Teresa Klinowska, Ph.D. Global Product Leader, Late Stage Oncology at AstraZeneca discussed the SABCS 20 abstract – SERENA-1 Phase I…
Helene Rundqvist of the Karolinska Institutet speaks about Cytotoxic T-cells mediate exercise-induced reductions in tumor growth.An abstract:Exercise has a large…
Antonio Llombart-Cussac, MD, Ph.D. Â founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova speaks about…
Antonio Llombart-Cussac, MD, Ph.D. founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova explains the…
Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology discussed…
Charles L. Shapiro MD, FASCO, Professor of Medicine, Hematology, Medical Oncology and Director of Translational Breast Cancer Research Icahn School…
Gerrit-Jan Liefers, MD of Leiden University Medical Center discusses the SABCS 2020 Abstract – The 70-gene signature (MammaPrint) accurately predicts…
Frankie Ann Holmes, MD, FACP from Texas Oncology-US Oncology Research speaks about Puma Biotechnology Presents Final Overall Survival Analysis from…
Pat Whitworth, MD of the Nashville Breast Center discusses the 5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint…
Stephanie A. Cohen, MS, LCGC from Ascension St. Vincent discusses the ACCC/ASCO 2020 abstract – [Abstract #1526] BRCA Testing Concordance…
Hope Rugo, MD of the University of California San Francisco speaks about the SABCS abstract – FDA Approves Merck’s KEYTRUDA®…
Chirag Shah, MD from the Cleveland Clinic discusses the SABCS 2020 abstract – DCIS biosignature reclassified patients who met RTOG…
Yuan Yuan, M.D., Ph.D., Medical Oncologist at the City of Hope discusses the SABCS 2020 abstract – Phase I study…
Erika J. Crosby, Ph.D. Department of Surgery at Duke University Medical Center and Melinda Telli, MD Medical Oncologist at Stanford…
Scott Howell, DO, MPH & TM, CPE from Echosens discusses Underlying nonalcoholic fatty liver disease is a significant factor for…
Shahid Gilani, MD from University Hospital Of North Midlands discusses the abstract Palbociclib in real world practice before and during…
Aditya Bardia, MD, MPH of Massachusetts General Hospital discusses the Natera Announces Collaboration with Massachusetts General Hospital for a Prospective…
Aditya Bardia, MD, MPH of Dana-Farber Cancer Institute speaks about ESMO 20 ASCENT: A randomized phase III study of sacituzumab…
Angel A. Rodriguez, MD, Oncology Medical Director of Natera speaks about Natera Announces Collaboration with Massachusetts General Hospital for a…
Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology speaks…
Murray Brunt, MBBS, FRCR, FRCP The Institute of Cancer discusses an article in The Journal of Clinical Oncology entitled Ten-Year…
Paola Nix, Ph.D. at Myriad Genetics discusses an ASCO 2020 abstract entitled Functional RNA Studies Are a Useful Tool in…
Jeff Ross, MD at Foundation Medicine discusses an ASCO 2020 abstract entitled Clinically aggressive malignancies associated with STK11 germline mutations…
Charles Edward Geyer, MD Houston Methodist discusses the ASCO 2020 abstract entitled Biomarker data from KATHERINE: A phase III study…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland…
In this episode of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS) held December 10…
In this edition of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS), held December 10…
Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast…
Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for…
Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for…
Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients…
Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Cathy L. Graham, MD of Winship Cancer Institute @WinshipAtEmory discusses basal subtype and clinical estrogen receptor status of genomically basal…
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated…
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage…
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients…